Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00612391
Other study ID # HURA1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 2007
Est. completion date November 2020

Study information

Verified date April 2021
Source Université de Montréal
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A prospective randomized clinical trial is proposed to compare the plate fixation of proximal humerus fractures using a minimally invasive lateral approach and the traditional anterior approach.Forty five patients will be assigned to each approach (total of 90 patients) and will be assessed 7 times over a two-year period. The trial's primary objectives will be to demonstrate the efficacy of the plating technique in terms of speed of recuperation of function. The Quick DASH will be used for evaluation of function.The study will also examine secondary end-points of pain, range of motion, esthetic satisfaction and radiographic outcome, as assessed by the components of the Constant Score3,4, SF-12V2 Questionnaire, and Patient Scare Assessment Scale Questionnaire. Furthermore, the assessment of safety will be based on the rates of all reported complications and adverse events at 2 years


Recruitment information / eligibility

Status Completed
Enrollment 79
Est. completion date November 2020
Est. primary completion date July 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Humeral surgical neck fracture, Neer II valgus-type Neer III 2. Patient willing to participate in the study 3. Patient available for follow-up through at least two years 4. Patient with acceptable preoperative medical clearance and free of, or treated for, medical conditions that would pose excessive operative risk 5. Patient fluent in French and/or English and able to understand his/her role in the study Exclusion Criteria: 1. Inflammatory arthritis 2. Prior shoulder pathology 3. Active local or systemic infection 4. Neurologic or musculoskeletal disease that may adversely affect mobility 5. Participation in any other pharmaceutical, biologic or medical-device clinical investigation 6. Severe documented psychiatric disease 7. Severe ipsilateral elbow or wrist disease 8. Fracture resistant to reduction attempts through the minimally invasive lateral approach

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Lateral minimally invasive approach (plate fixation)
A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
Deltopectoral approach (plate fixation)
Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.

Locations

Country Name City State
Canada Hopital Sacré-Coeur Montreal Quebec

Sponsors (3)

Lead Sponsor Collaborator
Université de Montréal Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Hopital du Sacre-Coeur de Montreal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quick DASH 3, 6, and 12 weeks, and at 6, 12, 18 and 24 months.
Secondary SF-12V2 Questionnaire Constant Shoulder Score The Patient Scar Assessment Scale Complication rate 3, 6, and 12 weeks, and at 6, 12, 18 and 24 months.